Onyx Pharma SURPASSING Expectations and 4 Stock Analyses to Note

Lowe’s Companies Inc. (NYSE:LOW) price target has been reduced by Baird after its Q2 results. The firm mentioned its struggles with its merchandising transformation but stated that Q3 comps and sales trends are off to a solid start. Also, Baird added that investor sentiment is still poor but its risk/reward appears favorable. Shares keep an Outperform rating.

Don’t Miss: Wall Street Brief: Peter Thiel DUMPS Facebook Shares, Apple’s Fate Still Undecided.

HollyFrontier (:HFC) target has been raised by Argus after the company reported higher Q2 EPS than expected. The firm raised its 2012 EPS estimate to $6.55 from $5.30 to represent the higher than expected Q2 EPS along with larger than expected crack spreads, and it keeps a Buy rating on the stock.

Salesforce.com (NYSE:CRM): According to JMP Securities, its checks during the quarter on Salesforce.com are still positive before the company’s report which is due on Thursday. JMP also thinks that the company is positioned to pause from acquisitions such as the Buddy Media purchase, which should be seen as positive by investors. The firm reiterates a Market Outperform rating on the stock.

Church & Dwight Co. Inc. (NYSE:CHD): Following the agreement of Church & Dwight to buy vitamin maker Avid Health, BMO Capital believes that Church & Dwight has finally found an acquisition target to leverage what the firm sees as its strong balance sheet. The firm maintains a Market Perform rating on Church & Dwight.

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX): After conducting a survey, Jefferies believes that uptake of Onyx’s Kyprolls will exceed expectations during 2013-2014. The firm thinks that the company could greatly surpass Street estimates, and the stock may see a meaningful appreciation. Jefferies maintains a $101 target and Buy rating on the shares.

Don’t Miss: Judge: Google Has FAILED.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.